Exon skipping oligomer conjugates for muscular dystropy

Abstract

Antisense oligomer conjugates complementary to a selected target site in the human dystrophin gene to induce exon 45 skipping are described.

Description

RELATED INFORMATION[0001]This patent application claims the benefit of U.S. Provisional Patent Application Ser. No. 62 / 436,199, filed Dec. 19, 2016, U.S. Provisional Patent Application Ser. No. 62 / 443,481, filed Jan. 6, 2017, U.S. Provisional Patent Application Ser. No. 62 / 479,177, filed Mar. 30, 2017, and U.S. Provisional Patent Application Ser. No. 62 / 562,119, filed Sep. 22, 2017. The entire contents of the above-referenced provisional patent applications are incorporated herein by reference.FIELD OF THE DISCLOSURE[0002]The present disclosure relates to novel antisense oligomer conjugates suitable for exon 45 skipping in the human dystrophin gene and pharmaceutical compositions thereof. The disclosure also provides methods for inducing exon 45 skipping using the novel antisense oligomer conjugates, methods for producing dystrophin in a subject having a mutation of the dystrophin gene that is amenable to exon 45 skipping, and methods for treating a subject having a mutation of the ...

AI Technical Summary

Benefits of technology

The patent text describes antisense oligomer conjugates that can be used to treat Duchenne muscular dystrophy (DMD) by inducing exon skipping in the dystrophin gene. These conjugates consist of an antisense oligomer that targets the exon 45 annealing site and is linked to a cell-penetrating peptide (CPP) through a linker moiety. The CPP can facilitate the delivery of the antisense oligomer into cells. The patent also provides pharmaceutical compositions and methods for using these conjugates for treating DMD. The technical effect of this patent is to provide a new and effective treatment for DMD that targets the underlying genetic mutation and promotes dystrophin production.

Problems solved by technology

However, such techniques are not useful where the object is to up-regulate production of the native protein or compensate for mutations that induce premature termination of translation, such as nonsense or frame-shifting mutations.

Any exonic mutation that changes the reading frame of the exon, or introduces a stop codon, or is characterized by removal of an entire out of frame exon or exons, or duplications of one or more exons, has the potential to disrupt production of functional dystrophin, resulting in DMD.

In general, dystrophin mutations including point mutations and exon deletions that change the reading frame and thus interrupt proper protein translation result in DMD.

Images